Conditions & Treatments
Learn from the Experts
Support Your Practice
Conferences & Highlights
CME Activities
Educational Resources
Community Resources
Our Expert Network
-
Summary In the video, Dr. Darrell Rigel explains that the 40-GEP test is a new approach to assess prognosis with squamous cell carcinoma. The test utilizes gene expression profiles (genomics) to provide additional information beyond traditional clinical and histologic factors. By incorporating genomics, the 40-GEP test offers an extra dimension to better evaluate the prognosis of patients with squamous cell carcinoma, potentially leading to more accurate and personalized treatment decisions. Key Points The 40-GEP test is a test that utilizes gene expression profiles to assess prognosis in cases of squamous cell carcinoma. It represents a new approach in contrast to the traditional method of using clinical and histologic factors to determine prognosis. The test offers an advantage by introducing genomics as an additional dimension to improve the accuracy of prognosis assessment. The term "40-GEP" refers to the specific gene expression profile that is analyzed in the test. By incorporating genomic information, the 40-GEP test aims to provide a more comprehensive and precise evaluation of the prognosis for squamous cell carcinoma patients.
Summary In the video, Dr. Darrell Rigel discusses the significance of better assessing the prognosis of squamous cell carcinoma (SCC), including cutaneous SCC. He emphasizes that SCC is a serious disease and can lead to fatalities. Therefore, it is crucial to have an accurate prognosis assessment to determine which patients require further therapy. Understanding the prognosis allows healthcare professionals to provide appropriate and timely treatment for those affected by SCC. Key Points Squamous cell carcinoma (SCC) is a serious disease, including cutaneous squamous cell carcinoma, and it can lead to fatalities. Accurate assessment of SCC prognosis is essential to determine the appropriate course of action for patients, including the need for further therapy. Prognosis assessment helps in identifying high-risk patients who may require more intensive treatments and monitoring. Early identification of patients with poor prognosis can potentially improve outcomes and increase survival rates. Tailoring treatment plans based on prognosis can help avoid over-treatment in low-risk cases and provide more aggressive approaches for high-risk cases. Monitoring prognosis allows healthcare professionals to make informed decisions and adjustments in treatment strategies as the disease progresses. Improved prognosis assessment contributes to a more personalized and effective approach to managing SCC patients. Research and advancements in prognosis assessment may lead to better understanding of SCC's behavior and potential new treatment options. Overall, accurate prognosis assessment is crucial for enhancing the management and outcomes of individuals with SCC.
Summary In the video, Dr. Darrell Rigel explains how the 40-GEP test functions. The test involves the analysis of 40 specific genes to evaluate their expression levels. These genes are used in combination with a proprietary formula to determine a patient's prognosis. Based on the results, patients are categorized into low-risk, medium-risk, or high-risk groups. This classification helps medical professionals make more accurate assessments and tailor the appropriate treatment plan accordingly. Key Points The 40-GEP test utilizes 40 specific genes. Its primary purpose is to assess prognosis in medical cases. The test evaluates the degree of gene expression in combination with a proprietary formula. The evaluation helps categorize patients into different risk groups: low risk, medium risk, or high risk. The results of the test allow healthcare professionals to tailor treatment plans based on the risk group the patient falls into. By understanding the patient's risk level, the therapy can be adjusted accordingly to optimize treatment outcomes.
Summary In this video, Dr. Darrell Rigel addresses the question of which squamous cell carcinomas (SCCs) are suitable for the 40-GEP test. He emphasizes that not all SCCs are appropriate for this particular test. The data used to develop the test was gathered from cases of advanced squamous cell carcinomas, specifically those that have at least one of the high-risk factors such as large diameter, significant depth, and other risk factors associated with advanced disease. The 40-GEP test is not intended for use with squamous cell carcinoma in situ or early-stage squamous cell carcinomas. Instead, it is specifically designed and validated for cases where there are indicators of advanced disease. Key Points SCCs (Squamous Cell Carcinomas) that are appropriate for the 40-GEP (Gene Expression Profiling) test are specific types of cases. The test's data was collected on advanced squamous cell carcinomas, which means it is not suitable for squamous cell carcinoma in situ (early stage) cases. It is specifically designed for squamous cell carcinomas that have at least one of the high-risk factors associated with advanced disease. The high-risk factors include diameter, depth, and other risk factors that indicate the likelihood of the carcinoma being in an advanced stage.
Summary Dr. Darrell Rigel discusses how he approaches the discussion of 40-GEP (Genomic Expression Profile) test results with his patients. He emphasizes the importance of having a frank conversation with the patients about their test results. The 40-GEP test results are relatively easy for patients to understand because they are categorized into three levels of risk: low risk, mid-risk, and high risk. Depending on which risk category the patient falls into, Dr. Rigel tailors his discussion accordingly. For patients with low-risk results, Dr. Rigel can confidently inform them that there is no need for advanced treatments or additional therapies beyond close monitoring. However, for patients in the mid-risk or high-risk category, he may discuss the possibility of additional therapies such as adjuvant radiation or the use of specific medications like cemiplimab, PD1 inhibitors, or other more advanced treatments. The primary goal of discussing these test results with patients is to provide them with a clear understanding of their risk level and prognosis. This information allows for informed decision-making regarding the necessity and potential benefits of further treatment options, ensuring the best possible care for each individual patient. Key Points 40-GEP test results are easy for patients to understand as they are categorized into three levels of risk: low, mid risk, and high risk. The degree of risk and prognosis are used to determine whether additional therapy is necessary, and the doctor should tailor their discussion with the patient accordingly. Treatment options discussed with mid to high-risk patients may include adjuvant radiation, cemiplimab, PD1 inhibitors, or more advanced treatments. For low-risk patients, the need for advanced treatments is deemed unnecessary, and close patient monitoring may suffice.
Summary In the video, Dr. Darrell Rigel addresses the question of whether the 40-GEP test is covered by Medicare. He explains that currently, there is insurance coverage available for some cases, but the specific coverage rules may vary depending on the Medicare coverage carrier. He mentions that over time, the coverage for the 40-GEP test is expected to become more clear and standardized. Dr. Rigel also mentions that the company offering the 40-GEP test accepts insurance as a form of payment. This approach is designed to make it easier for patients to access the test results without facing financial burdens. Key Points The 40-GEP test may be covered by Medicare, but the coverage is not consistent across all cases. Different Medicare coverage carriers have varying rules regarding the 40-GEP test's insurance coverage. The insurance coverage situation is expected to become more clear and standardized at some point in the future. The company conducting the 40-GEP test accepts insurance as a form of payment from patients.
Summary In the video "Why doesn't SCC get the respect it should?" Dr. Darrell Rigel discusses the lack of recognition that cutaneous squamous cell carcinoma (SCC) receives in comparison to other types of skin cancer. He likens SCC to the "Rodney Dangerfield" of skin cancer, meaning it doesn't receive the respect it deserves. The reason for this lack of recognition is that SCC falls in the middle between basal cell carcinoma (which has lower risk) and melanoma (which has a much higher risk). However, Dr. Rigel points out that the data shows almost as many people die from cutaneous squamous cell carcinoma in the United States as from melanoma. Although the percentage of SCC-related deaths may be lower due to the higher prevalence of SCC cases, the actual number of deaths is significant. This underscores the importance of better assessing the prognosis of cutaneous squamous cell carcinoma to raise awareness about its severity and address its impact on public health effectively. Key Points SCC (Squamous Cell Carcinoma) is often overlooked and does not receive the respect it deserves. One of the reasons for SCC's lack of attention is because it falls in the middle when comparing it to other skin cancers. Basal cell carcinoma is considered less risky, while melanoma is regarded as a higher-risk skin cancer. However, Dr. Rigel emphasizes the importance of recognizing that SCC is still a significant concern. In the United States, the number of deaths from cutaneous squamous cell carcinoma is almost as high as that of melanoma. The lower percentage of SCC-related deaths compared to melanoma can be attributed to the higher number of SCC cases overall (more contagious squamous cells). Dr. Rigel stresses the need to improve the assessment of prognosis for SCC to better understand and address its impact on public health.
Summary In the video, Dr. Darrell Rigel discusses the traditional prognostic paradigms for squamous cell carcinoma (SCC). Currently, the two commonly used criteria are the AJCC (American Joint Committee on Cancer) criteria and the Boston Women and Brigham's criteria. These criteria rely on assessing clinical and histopathologic factors such as the diameter of the lesion and the presence of perineural invasion, among other factors. However, Dr. Rigel points out that these traditional paradigms do not take into account genomic information. This is where the 40-GEP test comes into play. The 40-GEP test provides additional genomic information, which can be integrated into the prognosis assessment to improve accuracy. By incorporating genomic data, clinicians can gain valuable insights into the underlying genetic characteristics of SCC, leading to a more comprehensive and refined prognosis for patients. This advancement in prognostic evaluation may ultimately aid in better treatment decision-making and patient outcomes. Key Points Traditional SCC prognostic paradigms: AJCC criteria, Boston Women, and Brigham’s criteria. Assessment of prognosis for squamous cell carcinoma based on clinical and histopathologic factors. Factors used in traditional criteria include diameter of the lesion and perineural invasion involvement. Traditional methods lack consideration of genomics in prognosis assessment. The 40-GEP test provides additional genomic information for better and more accurate prognosis integration.
Summary Dr. Darrell Rigel discusses the trends in the incidence of cutaneous squamous cell carcinoma (SCC) in the United States. He states that the incidence of SCC is consistently increasing, particularly in the southern half of the country. This rising trend highlights the need to improve the identification of patients who are at the highest risk of developing metastatic disease and facing death due to SCC. By identifying these high-risk patients, healthcare providers can administer more aggressive therapies to appropriately treat the condition and improve patient outcomes. Key Points Cutaneous squamous cell carcinoma (SCC) incidence is on the rise in the United States. The increase in SCC incidence is particularly notable in the southern half of the country. Identifying patients at the highest risk for metastatic disease and death is becoming increasingly important. The goal is to treat high-risk patients with more aggressive therapy to improve outcomes. The rising trend in SCC calls for improved methods of identifying and diagnosing high-risk patients. Early detection and appropriate treatment are crucial in managing SCC cases effectively.
Summary Dr. Darrell Rigel explains in the video that the ideal patient for the 40-GEP test is someone who has a more advanced tumor. The main objective of this test is to identify individuals at the highest risk for metastatic disease. A class 2B result from the test indicates the highest risk, with a likelihood of 50 to 60% for metastatic disease. Therefore, the test is most appropriate for patients who already have an advanced tumor and have other risk factors associated with it. The test was not specifically designed for individuals with early-stage squamous cell carcinoma or squamous cell in situ, as the data was not collected for such cases. In summary, the 40-GEP test is recommended for patients with more advanced disease and additional risk factors for metastatic progression. Key Points The 40-GEP test is designed for patients with a more advanced tumor. The purpose of the test is to identify those at the highest risk for metastatic disease. A class 2B result from the 40-GEP test indicates the highest risk, with a 50 to 60% chance of metastatic disease. The ideal patient for the test is someone who already has an advanced tumor to some extent and has other risk factors for metastasis. The test is not suitable for individuals with squamous cell in situ or very early squamous cell cancer, as the data for the test was not collected for such cases. The focus of the 40-GEP test is on patients with more advanced disease to provide meaningful results.
